Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [7][15][17] - Net income for the full year was $316.9 million, compared to $444.1 million reported in 2024 [17] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024 [17] - GAAP diluted EPS was $2.50, compared with $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared with $4.23 in 2024 [17][18] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenues, representing 29% year-over-year growth, with total sales growing 22% to $14.4 billion [8][9] - PHESGO delivered $105.6 million in royalty revenue, reflecting 51% year-over-year growth, with total sales increasing 48% to approximately $3 billion [9][10] - VYVGART and VYVGART Hytrulo generated $157.2 million in royalty revenue, representing 444% year-over-year growth, with total sales growing 90% to $4.15 billion [10][11] Market Data and Key Metrics Changes - The company now has 10 ENHANZE-enabled global blockbuster opportunities, with significant approvals in the U.S., Japan, and China [6][12] - Roche reported that there are now 17,500 patients on Ocrevus Zunovo, a 5,000 patient increase from the third quarter [11] - Analysts project that PHESGO will reach CHF 3.6 billion in 2028, and Ocrevus franchise sales expectations have been increased to CHF 9 billion, or approximately $11.5 billion [10][12] Company Strategy and Development Direction - The company expanded its portfolio from two to four subcutaneous drug delivery technologies through acquisitions, positioning itself as a one-stop shop for biopharma subcutaneous drug delivery [5][6] - The focus is on advancing the ENHANZE pipeline, with projections for 6 new ENHANZE programs entering phase one in 2026 [21][32] - The company aims to continue strategic M&A to enhance its drug delivery portfolio and maintain financial discipline while investing in long-term value creation [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers that will support durable royalty revenue [20][36] - The company anticipates continued strong growth from its existing blockbusters and new product launches, with a focus on expanding into new therapeutic areas [20][21] - Management expects to enter discussions with Johnson & Johnson to extend the DARZALEX collaboration agreement closer to its expiration in 2032 [39][40] Other Important Information - The company signed three new ENHANZE collaboration and licensing agreements, expanding its reach beyond oncology into obesity and inflammatory bowel disease [6][7] - The acquisition of Surf Bio is expected to enhance the company's hyperconcentration technology capabilities [24] - The company ended the year with a net debt to EBITDA ratio of 2.1x, with expectations to deleverage to below 1x by the end of 2026 [19] Q&A Session Summary Question: Can you elaborate on the mechanics of the DARZALEX collaboration with J&J? - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, as they do not anticipate J&J seeking another source of API [39][40] Question: What are the regulatory paths for ADCs with ENHANZE? - The regulatory pathway for converting from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, while additional benefits would require phase trials [46][47] Question: What is the progress on Hypercon products? - The company is on track to support two partners in advancing to phase 1 clinical testing in 2026, with clinical scale-up batches being completed [61][62] Question: How will sales from auto-injectors be reported? - Sales from auto-injectors will be recognized similarly to API sales, with royalties recognized on commercial sales [76]

cbdMD (NYSEAM:YCBD) Q1 2026 Earnings call February 17, 2026 04:20 PM ET Company ParticipantsBrad Whitford - Chief Accounting Officer, Treasurer, and SecretaryRonan Kennedy - CEO and CFOThomas McGovern - Equity Research AssociateOperatorGood afternoon. Welcome, ladies and gentlemen, to cbdMD, Inc.'s December 31st, 2025, First Fiscal Quarter of 2026 earnings call and update. This afternoon, the company issued a press release that provided an overview of its first quarter results, which followed the filing of ...

Financial Data and Key Metrics Changes - For the first quarter of fiscal 2026, net sales totaled $5 million, a 12% sequential increase from the fourth quarter of fiscal 2025, but a slight decrease from $5.1 million in the prior year period [12] - Gross margin decreased to 60% from 66% in the prior year, primarily due to increased warehouse expenses and a shift in revenue mix towards wholesale [12] - Net loss attributable to common shareholders improved to approximately $325,000, or $0.04 per share, compared to a net loss of approximately $1 million, or $1.73 per share in the prior year quarter [13] Business Line Data and Key Metrics Changes - Direct-to-consumer sales represented approximately 72% of total revenue, while wholesale business accounted for 28% of revenue, showing a year-over-year growth of 17% [5] - The wholesale growth reflects improved execution in the core cbdMD brand and ongoing progress with the beverage brand, Oasis [5] Market Data and Key Metrics Changes - The company reported three consecutive quarters of sequential revenue growth, indicating positive trends in the business despite a challenging regulatory environment [4] - December 2025 and January 2026 marked the highest monthly revenue levels since 2022, suggesting a recovery in core business performance [4] Company Strategy and Development Direction - The company is focused on reducing fixed costs, simplifying operations, and strengthening the balance sheet to position for regulated growth [5] - The acquisition of Bluebird Botanicals is seen as strategically important, adding incremental revenue and a loyal customer base, while also enhancing regulatory and scientific positioning [7][8] - The company aims to maintain separate brand identities for Bluebird and cbdMD to cater to different customer bases [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term runway supported by a strong cash position and the incremental benefits from the Bluebird acquisition [15] - The regulatory environment remains uncertain, but recent bipartisan efforts to revisit restrictive hemp legislation are viewed positively [10] - The company is focused on generating positive EBITDA and managing cash carefully to support sustainable operating results [14] Other Important Information - The company completed approximately $2.25 million in Series C Preferred financing, strengthening liquidity and working capital [9] - As of December 31, 2025, cash and cash equivalents increased to approximately $3.4 million, reflecting improved liquidity [14] Q&A Session Summary Question: Insights on the integration of Bluebird Botanicals - Management indicated that they have brought over some team members from Bluebird and see opportunities for growth by leveraging their expertise and improving marketing activities [19] Question: Plans for integrating e-commerce capabilities - The company intends to maintain Bluebird as a separate brand due to differences in customer bases, allowing for continued growth [22] Question: Contribution of the Oasis line of seltzers to sales - While Oasis is starting to contribute, it remains small relative to the overall size of the core cbdMD brand, with expectations for improvement throughout the year [24]

cbdMD (NYSEAM:YCBD) Q1 2026 Earnings call February 17, 2026 04:20 PM ET Speaker1Good afternoon. Welcome, ladies and gentlemen, to cbdMD, Inc.'s December 31st, 2025, first fiscal quarter of 2026 earnings call and update. This afternoon, the company issued a press release that provided an overview of its first quarter results, which followed the filing of its quarterly report on, excuse me, on Form 10-Q. Today's conference call is being recorded and will be available online, along with our earnings press rele ...

Financial Data and Key Metrics Changes - The company converted over $7 million in one-time revenue to recurring SaaS, increasing recurring revenue from 62% to over 98% of total revenue [4] - Net margin grew from 8% to over 30% since 2020 [5] - GAAP net income for Q2 2026 was $1.7 million, up 9% from $1.6 million last year [9] - Total revenue for fiscal 2026 year-to-date increased 8% from $10.9 million to $11.8 million [11] - Earnings per share for the quarter was $0.09 basic and diluted, reflecting a 13% year-over-year growth [10] Business Line Data and Key Metrics Changes - The company is experiencing growth across all lines of business, with cross-selling initiatives contributing to momentum [12] - Traditional sales are growing, and the focus on customer care and execution remains paramount [12] Market Data and Key Metrics Changes - The traceability segment accounted for between 8% and 10% of total revenue [32] - The company is positioned to benefit from increasing consumer awareness regarding food safety, driven by trends like MAHA and organic food movements [38] Company Strategy and Development Direction - The company aims to maintain a focus on customer care, grow recurring revenue, and return capital to shareholders through dividends and stock buybacks [12] - Investments are being made in product development, including the filing of two patents for Touchless Traceability [7][24] - The company is preparing for an expected surge in demand for traceability solutions as FDA deadlines approach [49] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of data accuracy in traceability, with error rates from suppliers ranging from 50% to 70% [18] - The company believes that its AI-driven solutions for error detection and correction will provide a competitive advantage [22][35] - Management is cautious about the impact of food inflation on business but has not seen immediate effects [42] Other Important Information - The company has repurchased approximately 80,000 common shares for $1.1 million during Q2 2026 [13] - The board declared a quarterly dividend of $0.02 per share, marking the third 10% increase since the dividend was established [16] Q&A Session Summary Question: What is the current revenue contribution from traceability? - The revenue contribution from traceability is estimated to be between 8% and 10% [32] Question: Can AI improve the accuracy of traceability data? - AI can indeed improve accuracy by detecting and correcting errors in data, which is a significant advantage over traditional methods [34][35] Question: Is there any impact from MAHA on the business? - MAHA increases consumer awareness of food safety, which indirectly benefits the company [38] Question: Can the company provide updates on traceability by ingredients? - The company is capable of tracking products and ingredients, allowing for detailed specifications and compliance with FDA regulations [40] Question: Does food inflation impact the business? - Food inflation has an indirect impact, potentially leading to margin squeezes for supermarkets, which could affect the company's pricing [42] Question: How is investment spending reflected in the results? - Investment spending is more targeted, with less in marketing and more in development, leading to an overall reduction in aggregate spending [44][45] Question: What are the current thoughts on strategic M&A? - The company is focused on existing initiatives and does not see M&A as a priority at this time, although they remain open to opportunities [47][50]

Financial Data and Key Metrics Changes - For the second fiscal quarter of 2026, revenue increased by 7% from $5.5 million to $5.9 million [8] - Year-to-date total revenue increased by 8% from $10.9 million to $11.8 million [11] - GAAP net income for the second fiscal quarter was $1.7 million, up 9% from $1.6 million last year [9] - Earnings per share for the quarter was $0.09, reflecting a 13% year-over-year growth [10] - Total cash increased to $28.7 million from $28.6 million at the end of the previous quarter, with zero bank debt [10] Business Line Data and Key Metrics Changes - The company has converted over $7 million in one-time revenue to recurring SaaS, increasing recurring revenue from 62% to over 98% of total revenue [4] - Income from operations increased by 34% to $1.8 million compared to $1.4 million [9] - The company has experienced growth across all lines of business, with cross-selling initiatives delivering continued momentum [12] Market Data and Key Metrics Changes - Traceability revenue is estimated to be between 8% and 10% of total revenue, indicating growth in this segment [32] - The company is positioned to benefit from increasing consumer awareness regarding food safety, driven by trends like MAHA and organic food movements [38] Company Strategy and Development Direction - The long-term strategy focuses on converting revenue streams to SaaS, paying down debt, and increasing contribution margins [4] - The company is investing in product development, including new solutions for tracking accuracy and operational cost reduction [6] - The filing of two patents for Touchless Traceability aims to create a competitive moat around the business [7][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of achieving consistent accuracy in supplier data, with error rates between 50% and 70% [18] - The company anticipates increased demand for traceability solutions as the FDA deadline approaches, which is expected to accelerate onboarding and interest in their offerings [26][49] - Management remains confident in the company's ability to provide unique solutions that address data quality issues in traceability [22] Other Important Information - The company has repurchased approximately 80,000 common shares for $1.1 million during the second quarter [13] - A quarterly dividend of $0.02 per share was declared, marking the third 10% increase since the dividend was established [16] Q&A Session Summary Question: What is the current percentage of revenue from traceability? - Management indicated that traceability revenue is between 8% and 10% of total revenue [32] Question: Can AI improve the accuracy of traceability data? - Management confirmed that their AI tools can detect and correct errors in traceability data, enhancing accuracy [34][35] Question: What is the impact of MAHA on the business? - Management noted that increased consumer awareness of food safety due to MAHA positively impacts their business [38] Question: Can the company provide traceability on a by-ingredient basis? - Management confirmed that their system can track products and ingredients, allowing for detailed traceability [40] Question: Does food inflation impact the business? - Management acknowledged that food inflation indirectly affects their business, particularly if supermarkets face margin squeezes [42] Question: How is investment spending reflected in the results? - Management explained that investment spending is more targeted, with less in marketing and more in development, affecting overall expenses [44][45] Question: What are the current thoughts on strategic M&A? - Management stated that while they are open to opportunities, their current focus is on existing projects and preparing for upcoming demand in traceability [47][50]

Financial Data and Key Metrics Changes - The company converted over $7 million in one-time revenue to recurring SaaS, increasing recurring revenue from 62% to over 98% of total revenue since 2020 [4] - Net margin grew from 8% to over 30% during the same period [5] - GAAP net income for Q2 2026 was $1.7 million, up 9% from $1.6 million last year [9] - Fiscal 2026 year-to-date total revenue increased 8% from $10.9 million to $11.8 million [11] - Total cash increased to $28.7 million from $28.6 million at June 30, with zero bank debt [10] Business Line Data and Key Metrics Changes - The company is experiencing growth in all lines of business, with cross-selling initiatives delivering continued momentum [12] - Traditional sales are growing, and the focus on customer care and flawless execution remains paramount [12] Market Data and Key Metrics Changes - The ReposiTrak Traceability Network (RTN) is the industry leader, with a growing queue to join the network [16] - The company is addressing the challenge of data accuracy in traceability, with error rates from suppliers ranging between 50% and 70% [17] Company Strategy and Development Direction - The company aims to drive cash and return capital to shareholders while investing in product development and innovation [5][6] - Recent investments include filing for two patents related to Touchless Traceability, enhancing the company's competitive moat [6][23] - The focus on cross-selling and expanding the RTN is expected to generate significant traction [23] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges of data accuracy in traceability and the need for complex process changes across the supply chain [17] - The looming FDA deadline for traceability is expected to accelerate interest in the company's solutions [25][47] - The company is preparing for increased demand for traceability solutions as the deadline approaches [48] Other Important Information - The company has repurchased approximately 80,000 common shares for $1.1 million during Q2 2026 [13] - The board declared a quarterly dividend of $0.02 per share, marking the third 10% increase since the dividend was established [15] Q&A Session Summary Question: What is the current revenue contribution from traceability? - Management indicated that traceability contributes between 8% and 10% of total revenue [31] Question: Can AI improve the accuracy of traceability data? - AI is utilized to detect and correct errors in traceability data, enhancing accuracy significantly [32][34] Question: What impact does MAHA have on the business? - MAHA increases public awareness of food safety, which indirectly benefits the company [37] Question: Can the company provide updates on traceability by ingredients? - The company is capable of tracking products and ingredients, allowing for detailed specifications [39] Question: Does food inflation impact the business? - Food inflation indirectly affects the business as supermarkets face margin squeezes [41] Question: How is investment spending reflected in the results? - Investment spending is more targeted, with less in marketing and more in development [42][43] Question: What are the current thoughts on strategic M&A? - The company is focused on existing initiatives and is not actively pursuing M&A at this time [45][48]

Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $474 million, a 19.5% sequential increase driven by elevated sales activity [12] - Gross margin before inventory-related charges was over 19%, with an adjusted gross margin of over 22% [6][13] - Net income for Q4 was $17.3 million, or $0.75 per share, while excluding impairment-related charges, net income was $22.4 million, or $0.97 per share [15] Business Line Data and Key Metrics Changes - The company delivered 1,362 homes in Q4, with 1,301 contributing directly to revenue [5] - The average selling price of homes in Q4 was $364,000, slightly down compared to the previous year [12] - The wholesale business accounted for 12.1% of Q4 closings, generating significant revenue [12] Market Data and Key Metrics Changes - The cancellation rate increased to 43.3%, influenced by affordability pressures and economic uncertainty [9] - The backlog grew 133% to 1,394 homes, with a value exceeding $501 million, up 112% year-over-year [10] - The company ended the year with 144 active communities, averaging 3.1 closings per community per month in Q4 [8] Company Strategy and Development Direction - The company remains focused on managing costs, offering competitive financing options, and delivering affordable homes to first-time buyers [11] - Long-term outlook for the housing market remains positive, driven by supply-demand imbalance and favorable demographic trends [11] - The company plans to continue investing in people, land, and operating platforms to support long-term strategy [11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the dynamic market environment, with affordability being a primary pressure point [5] - The expectation for 2026 includes closing between 4,600 and 5,400 homes, with stable selling prices [23] - Management indicated that incentives will continue to be utilized to support affordability while maintaining margin discipline [23] Other Important Information - The company ended the year with $1.7 billion of debt outstanding and a net debt to capital ratio of 43.2% [20] - Total liquidity at year-end was $335 million, including over $61 million in cash [20] - The average finished lot cost is approximately $70,000, representing about 21% of the average selling price [18] Q&A Session Summary Question: Drivers of sequential decline in gross margin in Q4 - Management indicated that the decline was due to increased incentives and discounts on aged inventory [26][27] Question: Closings outlook for 2026 - Management expects a similar closings pace in 2026, with wholesale closings projected to be 10%-15% of total closings [29][31] Question: Profitability on wholesale orders - Management stated that gross margins on wholesale sales are lower, but operating margins are similar to retail [36] Question: Community count growth expectations for 2026 - New community openings are expected to be weighted towards the back half of the year [38] Question: Cancellations and reasons for cancellation - The cancellation rate is elevated primarily due to financing challenges faced by buyers [44][45] Question: Mix of first-time versus move-up buyers - The proportion of move-up buyers is increasing due to elevated entry-level price points [50] Question: Current market conditions and discounting - Management noted that affordability pressures remain, with competitors also leaning into incentives [53][54] Question: Year-over-year decline in G&A - Management indicated that G&A run rate for 2026 is expected to be similar to 2025 [56]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $474 million, representing a 19.5% sequential increase driven by elevated sales activity [11] - Gross margin before inventory-related charges was over 19%, with an adjusted gross margin of over 22%, although these were below guidance ranges due to the impact of buydowns and price discounts on older inventory [5][6] - Net income for Q4 was $17.3 million, or $0.75 per share, while excluding impairment-related charges, net income was $22.4 million, or $0.97 per share [14] Business Line Data and Key Metrics Changes - In Q4, 1,362 homes were delivered, with 1,301 contributing directly to reported revenue [4] - The average selling price for Q4 closings was $364,000, slightly down compared to the previous year [11] - The wholesale business accounted for 12.1% of Q4 closings, generating significant revenue [11] Market Data and Key Metrics Changes - The cancellation rate increased to 43.3%, attributed to affordability pressures and economic uncertainty [8] - The backlog grew 133% to 1,394 homes, with a value exceeding $501 million, up 112% year-over-year [9] Company Strategy and Development Direction - The company remains focused on managing costs, offering competitive financing options, and delivering affordable homes to first-time buyers [10] - Long-term outlook for the housing market remains positive, driven by supply-demand imbalance and favorable demographic trends [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by affordability and rate volatility but expressed confidence in the company's ability to navigate these issues [4] - For 2026, the company expects to close between 4,600 and 5,400 homes, with stable selling prices and continued use of incentives to support affordability [22][23] Other Important Information - The company ended the year with $1.7 billion of debt and a net debt to capital ratio of 43.2% [19] - Total liquidity at year-end was $335 million, including cash on hand and revolver availability [19] Q&A Session Summary Question: Drivers of sequential decline in gross margin in Q4 - Management indicated that the decline was due to increased incentives and discounts on aged inventory, with expectations for similar conditions in 2026 [26][27] Question: Closings outlook for 2026 - Management confirmed expectations for a similar closings pace in 2026, with wholesale business contributing 10%-15% of total closings [28][30] Question: Profitability on wholesale orders - Management stated that operating margins for wholesale business are similar to retail, but gross margins are lower [35] Question: Community count growth expectations for 2026 - New community openings are expected to be weighted towards the back half of the year, with confidence in achieving the community count guidance [37] Question: Cancellations and buyer financing issues - Management noted that cancellations are primarily due to buyers' ability to secure financing, with customers taking longer to close [43][44] Question: Current market conditions and discounting - Management acknowledged ongoing aggressive discounting in the market, with affordability pressures remaining a significant concern [52] Question: Year-over-year decline in G&A - Management indicated that G&A run rate for 2026 is expected to be similar to 2025, with some fluctuations quarter to quarter [55]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $474 million, representing a 19.5% sequential increase driven by elevated sales activity [10] - Gross margin before inventory-related charges was over 19%, with an adjusted gross margin of over 22%, both below guidance ranges due to the impact of buydowns and price discounts on older inventory [5][11] - Pre-tax net income was $24 million, or 5.1% of revenue, with net income of $17.3 million, or $0.75 per share [13] Business Line Data and Key Metrics Changes - The company delivered 1,362 homes in Q4, with 1,301 contributing to reported revenue [4] - The average selling price for Q4 closings was $364,000, slightly down from the previous year [10] - The wholesale business accounted for 12.1% of Q4 closings, generating significant revenue [10] Market Data and Key Metrics Changes - The cancellation rate increased to 43.3%, attributed to affordability pressures and economic uncertainty [7] - The backlog grew 133% to 1,394 homes, with a value exceeding $501 million, up 112% year-over-year [8] Company Strategy and Development Direction - The company remains focused on managing costs, offering competitive financing options, and delivering affordable homes to first-time buyers [9] - Long-term outlook for the housing market remains positive, driven by supply-demand imbalance and favorable demographic trends [9] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges of affordability and rate volatility but expressed confidence in the company's ability to navigate these issues [4] - For 2026, the company expects to close between 4,600 and 5,400 homes, with stable selling prices and a focus on maintaining margins [21] Other Important Information - The company ended the year with $1.7 billion in debt and a net debt to capital ratio of 43.2% [19] - Total liquidity at year-end was $335 million, including cash on hand and revolver availability [19] Q&A Session Summary Question: What drove the sequential decline in gross margin in Q4? - Management indicated that the decline was due to increased incentives and discounts on aged inventory, along with competitive pricing pressures [26] Question: What is the outlook for closings in 2026? - Management confirmed expectations for a similar closings pace in 2026, with wholesale closings projected to be 10%-15% of total closings [28] Question: How will profitability be affected by the 480 orders in the wholesale business? - Management stated that while gross margins are lower for wholesale sales, operating margins remain similar to retail [34] Question: What is the current mix of first-time versus move-up buyers? - Management noted an increase in move-up buyers due to elevated entry-level price points, although first-time buyers still dominate [49] Question: What are the current conditions regarding affordability and discounting? - Management acknowledged ongoing affordability challenges and the need for continued incentives to assist buyers [52]